Table 3

Multivariate adjusted ORs of non-cirrhotic hepatocellular carcinoma (HCC) and cirrhotic-HCC‡

Non-cirrhotic-HCC (Group III vs Group I)*Cirrhotic-HCC (Group IV vs Group I)†
Control (n=2789)Case (n=370)OR (95% CI)p ValueControl (n=2789)Case (n=410)OR (95% CI)p Value
rs2296651 (S267F)
 GG2274 (81.5)321 (86.8)1.002274 (81.5)358 (87.3)1.00
 GA/AA515 (18.5)49 (13.2)0.65 (0.46 to 0.91)0.01515 (18.5)52 (12.7)0.48 (0.33 to 0.69)<0.001
Age, mean years (SD)45.1 (9.64)49.8 (11.0)1.06 (1.05 to 1.08)<0.00145.1 (9.64)51.5 (9.44)1.10 (1.08 to 1.11)<0.001
Gender
 Female1125 (40.3)131 (35.4)1.001125 (40.3)106 (25.9)1.00
 Male1664 (59.7)239 (65.6)1.07 (0.84 to 1.38)0.581664 (59.7)304 (74.2)2.03 (1.53 to 2.69)<0.001
Serum alanine aminotransferase level, U/L
 <452656 (95.2)261 (70.5)1.002656 (95.2)255 (62.2)1.00
 ≥45133 (4.77)109 (29.5)6.64 (4.84 to 9.10)<0.001133 (4.77)155 (37.8)7.68 (5.60 to 10.53)<0.001
HBV DNA level, copies/mL
 <300769 (27.6)31 (8.38)1.00769 (27.6)22 (5.37)1.00
 300–9999943 (33.8)83 (22.4)2.45 (1.59 to 3.79)<0.001943 (33.8)52 (12.7)2.27 (1.34 to 3.83)0.002
 10 000–99 999498 (17.9)79 (21.4)4.18 (2.68 to 6.52)<0.001498 (17.9)72 (17.6)5.86 (3.51 to 9.79)<0.001
 ≥100 000579 (20.8)177 (47.8)7.42 (4.88 to 11.29)<0.001579 (20.8)264 (64.4)16.32 (10.11 to 26.36)<0.001
  • *Multivariate analysis of the association between S267F and non-cirrhotic HCC was performed, comparing patients who developed non-cirrhotic HCC (Group III) to patients without liver cirrhosis and HCC (Group I).

  • †Multivariate analysis of the association between S267F and cirrhotic HCC was performed, comparing patients who developed cirrhotic HCC (Group IV) to patients without liver cirrhosis and HCC (Group I).

  • ‡HBsAg titre, HBeAg serostatus and HBV genotype were not included in this analysis due to the unavailability of these data in the Taiwan Liver Cancer Network (TLCN) cohort.

  • HBeAg, hepatitis B e antigen; HBsAg, hepatitis B surface antigen.